Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis

Summary

Bivalirudin, a direct thrombin inhibitor binds specifically and reversibly to both fibrin-bound and unbound thrombin. Bivalirudin is approved for use as an anticoagulant in patients undergoing percutaneous coronary intervention. The OASIS-5 trial presented a significant increase in cardiac catheter thrombosis for the pentasaccharid fondaparinux compared to enoxaparin. Catheter thrombosis has never been reported in any trial using bivalirudin. Our study compared the development of catheter thrombosis for bivalirudin, enoxaparin, and unfractionated heparin in a controlled in-vitro environment. Ten healthy male volunteers were pretreated with aspirin 500 mg 2 hours before venesection of 50 ml of blood. The seven groups of anticoagulant combinations tested were:UFH, UFH + eptifibatide, enoxaparin, enoxaparin + eptifibatide, bivalirudin bolus, bivalirudin + eptifibatide, bivalirudin bolus + continuous infusion. The blood/anticoagulant mix continuously circulated through a cardiac guiding catheter for 60 minutes or until the catheter became blocked with thrombus. Thrombus development was assessed by weighing each catheter before and after the procedure. Electron microscopy was used to quantify the degree of erythrocyte, platelet and fibrin deposition. Following anticoagulation with bolus dose bivalirudin, the catheter was invariably occluded with thrombus after 33 minutes of circulation. However, a continuous infusion of Bivalirudin prevented the development of occlusive catheter thrombosis. In the bolus bivalirudin group the mean thrombus weight was significantly greater than in all other groups (p-value < 0.01 in all analyses). Bivalirudin given as a bolus was not sufficient to prevent cardiac catheter thrombosis in our in-vitro study. However, a continuous infusion of bivalirudin had similar anti-thrombotic efficacy compared to other treatment strategies.

Keywords

Cardiology - heparins - coagulation inhibitors - drug design - thrombosis

• References

• 1 Bassand JP, Hamm CW, Ardissino D. et al. Task Force for Diagnosis and Treatment of non-ST-Segment elevation Acute Coronary Syndromes of European Society of Cardiology- Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Europ Heart J 2007; 13: 1598-1660.
• 2 Yusuf S, Mehta SR, Chrolavicius S. et al. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparisonoffondaparinuxand enoxaparinin acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
• 3 Schlitt A, Maegdefessel L, Buerke M. et al. In vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter associated thrombus. Coron Artery Dis 2008; 19: 279-284.
• 4 Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clinical Therapy 2002; 24: 38-58.
• 5 Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother 2002; 36: 1028-1041.
• 6 Lepor NE. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev Cardiovasc Med 2007; 08: 9-17.
• 7 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes-ACUITY Investigators. N Engl J Med 2006; 355: 2203-2216.
• 8 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 2003; 289: 853-863.
• 9 Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. Coron Artery Dis 2006; 17: 471-476.
• 10 Kuchulakanti PK, Satler LF, Waksman R. et al. Bivalirudin-associated intracoronary thrombosis during gamma-brachytherapy and its experimental validation in acute swine model. Catheter Cardiovasc Interv 2004; 62: 209-213.
• 11 Kuchulakanti PK, Wolfram R, Waksman R. et al. Brachytherapy and bivalirudin evaluation study-The BRAVES Trial. Am Heart J 2005; 150: 832-837.
• 12 Choy JB, Armstrong PW. Anticoagulant therapy in unstable angina. Cardiol Clin 1999; 17: 327-343.
• 13 Lincoff AM, Kleiman NS, Topol EJ. et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-853.
• 14 Schlitt A, Maegdefessel L, Rupprecht HJ. et al. Comparison of fondaparinux, low molecular weight heparin and unfractioned heparin in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Heart Valve Dis 2006; 15: 809-814.
• 15 Schlitt A, Buerke M, Rupprecht HJ. et al. Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Res 2002; 107: 39-43.
• 16 Schlitt A, Buerke M, Rupprecht HJ. et al. Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Haemost 2003; 90: 245-251.
• 17 Nappi J. The biology of thrombin in acute coronary syndromes. Pharmacotherapy 2002; 22: 90-96.
• 18 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-174.
• 19 Kong DF, Topol EJ, Bittl JA. et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100: 2049-2053.
• 20 Kleiman NS, Klem J, Fernandes LS. et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002; 143: 585-593.
• 21 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infraction-The HORIZONS-AMI Trial Investigators. N Engl J Med 2008; 358: 2280-2282.
• 22 Yusuf S, Mehta SR, Fox KA. et al. The OASIS-6 Trial Group. Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST - Segment Elevation Myocardial Infarction: The OA SIS-6 Randomized Trial. J Am Med Assoc 2006; 295: 1519-1530.
• 23 Stief TW. Kallikrein activates prothrombin. Clin Appl Thromb Haemost 2008; 14: 97-98.
• 24 Røjkjaer R, Hasan AA, Schmaier AH. et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
• 25 Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation?. Thromb Haemost 2008; 99: 457-460.
• 26 Kleinschnitz C, Stoll G, Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 493-495.
• 27 Shousboe I. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. Biochem Pharmacol 2008; 75: 1007-1013.
• 28 Warkentin TE, Greinacher A, Ofosu FA. et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005; 94: 958-964.
• 29 Ofosu FA, Liu L, Freedman J. et al. Control mechanisms in thrombin generation. Semin Thromb Hemost 1996; 22: 303-308.
• 30 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
• 31 Thrall G, Lane D, Lip GY. et al. A systematic review of the effects of acute physiological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. Thromb Res 2007; 120: 819-847.
• 32 Mann KG, Brummel-Ziedins K, Butenas S. et al. Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108-117.
• 33 Fenton 2nd JW, Ofosu FA, Hassouna HI. et al. Thrombin and antithrombotics. SeminThromb Hemost 1998; 24: 87-91.